Key result
Combined IFG and IGT was associated with higher odds of left ventricular hypertrophy compared to normal glucose tolerance.
Why the study?
Is impaired fasting glucose or combined IFG and IGT associated with progressive abnormalities of cardiac geometry and function in nondiabetic, nonhypertensive individuals?
Cross-Sectional (n=562)
Is impaired fasting glucose or combined IFG and IGT associated with progressive abnormalities of cardiac geometry and function in nondiabetic, nonhypertensive individuals?
Answers are grounded in this paper and cite their sources.
Individuals with combined impaired fasting glucose and impaired glucose tolerance, even without hypertension or diabetes, have a nearly 10-fold higher odds of preclinical cardiovascular disease (LV hypertrophy).
OBJECTIVE: To evaluate whether impaired fasting glucose (IFG) or the combination of IFG and impaired glucose tolerance (IGT) is associated with progressive abnormalities of cardiac geometry and function. RESEARCH DESIGN AND METHODS: We studied 562 nondiabetic (311 women), nonhypertensive participants of the second Strong Heart Study exam, without prevalent cardiovascular (CV) disease and with estimated glomerular filtration rate ≥60 mL/min/1.73 m(2) (age 46-65 years, 198 with isolated IFG [35%], and 132 with combined IFG and IGT [23%]). Anthropometric parameters, insulin resistance, fibrinogen, C-reactive protein (CRP), lipid profile, blood pressure (BP), and echocardiographic parameters were compared with 232 participants with normal glucose tolerance (NGT). RESULTS: BMI, prevalence of central obesity, homeostatic model assessment index of insulin resistance, plasma triglycerides, fibrinogen, and CRP increased progressively across categories of glucose intolerance (P < 0.0001), with the IFG+IGT group having higher values than those with isolated IFG (0.05 < P < 0.0001). Compared with NGT, both IFG and IFG+IGT exhibited greater left ventricular (LV) mass (P < 0.0001) and lower Doppler early peak rapid filling velocity to peak atrial filling velocity ratio (P < 0.005), without differences in LV systolic function. The odds of LV hypertrophy (LV mass index >46.7 in women or >49.2 g/m(2.7) in men) was 3.5 in IFG participants (95% CI 0.68-17.76; P = NS) and 9.76 (2.03-46.79; P = 0.004) in IFG+IGT, compared with NGT, after adjustment for age, sex, heart rate, systolic BP, and waist circumference (WC). In the overall sample, LV mass index was associated with WC (P = 0.033), CRP (P = 0.027), and 2-h oral glucose tolerance test (P = 0.001) independently of confounders. CONCLUSIONS: Cardiometabolic profile and markers of inflammation are more severely altered in men and women with both IFG and IGT compared with those with IFG alone. These individuals, in the absence of hypertension, have a 10-fold greater probability of preclinical CV disease (LV hypertrophy).
No takes yet. Share an insight, caveat, or question.
Capaldo et al. (2012) conducted a cross-sectional in Abnormal Glucose Regulation (n=562). Combined impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) vs. Normal glucose tolerance (NGT) was evaluated on Left ventricular (LV) hypertrophy (OR 9.76, 95% CI 2.03-46.79, p=0.004). Combined IFG and IGT was associated with higher odds of left ventricular hypertrophy compared to normal glucose tolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: